Newport Pharmaceuticals Limited provides products for the treatment of infectious diseases, immunological disorders, and related conditions.

It is focused on the manufacture and supply of IAD – Inosine Acedoben Dimepranol, a synthetic purine derivative.

The company sells its products through a network of licensees and distributors in Austria, Belgium, France, Germany, Greece, Ireland, Italy, Luxemburg, Portugal, the United Kingdom, Canada, Japan, Bahrain, Egypt, Kuwait, and the United Arab Emirates.

Newport Pharmaceuticals is the group Technical and Business Support arm of the Ewopharma Group.  Newport’s core competencies are in Manufacture and Supply Chain Management, Batch Release, Quality Assurance, Regulatory, Pharmacovigilance, Healthcare Compliance and Legal.

Company Name
Newport Pharmaceuticals Limited

Unit A4, Swords Enterprise Park, Feltrim Road, Swords, Co. Dublin

LBS Partners

IDA Ireland

Quote – The Lean Start programme has been a positive experience for Newport leading to new learnings and effective team work.  It has equipped Newport with the tools to continue on its journey as a high performance service provider and grow the company.

We would definitely recommend Lean Start to other companies.


Lean Start Project Objectives
  • To mitigate risk to the reputation of Ewopharma group, to enhance the reputation of Ewopharma group
  • To reduce risk to business operations from regulatory non-compliance leading to loss of suspension of licences.
  • To eliminate waste and non-value added steps to increase capacity and productivity/ efficiency
  • To achieve customer satisfaction, To form effective teams
Key Challenges
  • To manage the project across a wide geographical distribution of key stakeholders
  • To change the company culture and overcome resistance to change.
Key Changes
  • Application of lean principles
  • Improved process definition and documentation
  • Creation of cross functional teams
  • The third party complaints process team eliminated bottlenecks, training gaps and communication gaps to deliver an effective and efficient process for managing complaints and significantly reduced the risk of adverse findings/ business impact during regulatory and partner audits.
  • The compliance query process team identified and eliminated duplication, poor communication and poor scope control, by redesigning the process. These improvements will increase capacity to meet the growing business needs and realise annual savings of up to €25,000